MTAP and lung adenocarcinoma: Furthermore, Omar Alhalabi et al. conducted an analysis on a cohort of lung adenocarcinoma patients, observing a statistically significant increase in response rates to frontline platinum-based chemotherapy regimens, including pemetrexed, in subjects with reduced CDKN2A/MTAP expression, indicative of 9p21 loss.